Nivolumab/Ipilimumab in Second Line CUP-syndrome
NCT04131621
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
194
Enrollment
OTHER
Sponsor class
Conditions
Cancer of Unknown Primary Site
Interventions
BIOLOGICAL:
Nivolumab/Ipilimumab
Sponsor
University Hospital Heidelberg